Category: Investor updates

“Appendix 3B, New issue announcement, application for quotation of additional securities and agreement” of 6th June, 2018, is posted. View and download Appendix 3B, New issue

Viriathus Research has published a 29-page Overview Report on Imagion Biosystems Limited. This detailed report includes close examinations of the company’s business and investment potential,

In accordance with Listing Rule 3.10A, Imagion Biosystems Limited (the Company) advises that 3,483,333 fully paid ordinary shares in the Company, which are unquoted and

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001 (Cth), Imagion Biosystems Limited (ASX: IBX) (the Company) advises the results

The investor presentation “MagSense® Technology: A New Diagnostic for Targeted Early Detection of Cancer” was presented at the 2017 Annual General Meeting. View the Investor

From Chairman Bob Proulx’s Address to Shareholders at the 2018 Annual General Meeting, held 31 May, 2018: “We all know that far to many people’s

Further to Imagion Biosystems Limited’s announcement dated 23 May 2018, the Company advises of an amendment to Resolution 9 of its Notice of Annual General

Imagion Biosystems Limited has lodged Appendix 3X, Final Director’s Interest Notice, with the Australian Securities Exchange. View the Final Director’s Interest Notice.

Imagion Biosystems Limited has lodged Appendix 3X, Initial Director’s Interest Notice, with the Australian Securities Exchange. View the Initial Director’s Interest Notice.